ID

34993

Descrição

MM-302 Plus Trastuzumab vs. Chemotherapy of Physician's Choice Plus Trastuzumab in HER2-Positive Locally Advanced/Metastatic Breast Cancer Patients; ODM derived from: https://clinicaltrials.gov/show/NCT02213744

Link

https://clinicaltrials.gov/show/NCT02213744

Palavras-chave

Versões (1)
  1. 07/02/2019 07/02/2019 -
Titular dos direitos

See clinicaltrials.gov

Transferido a

7 de fevereiro de 2019

DOI

Para um pedido faça login.

Licença

Creative Commons BY 4.0
Comentários do modelo :

Aqui pode comentar o modelo. Pode comentá-lo especificamente através dos balões de texto nos grupos de itens e itens.

Voltar para os comentários do modelo
Comentários do grupo de itens para :

Comentários do item para :

Para descarregar formulários, precisa de ter uma sessão iniciada. Por favor faça login ou registe-se gratuitamente.

Eligibility Breast Cancer NCT02213744

Inglês

Eligibility Breast Cancer NCT02213744

1 Formulários  
Inclusion Criteria
Descrição

Inclusion Criteria

Alias
UMLS CUI
C1512693
patients must have histologically or cytologically confirmed invasive cancer of the breast
Descrição

Invasive carcinoma of breast

Tipo de dados

boolean

Alias
UMLS CUI [1]
C0853879
patients must have documented locally advanced/metastatic disease, defined by the investigator, which is not amenable to resection with curative intent.
Descrição

Advanced disease Locally | Neoplasm Metastasis | Excision Curative intent Unsuccessful

Tipo de dados

boolean

Alias
UMLS CUI [1,1]
C0679246
UMLS CUI [1,2]
C1517927
UMLS CUI [2]
C0027627
UMLS CUI [3,1]
C0728940
UMLS CUI [3,2]
C1276305
UMLS CUI [3,3]
C1272705
patients must have her2-positive breast cancer as defined by asco/cap 2013 guidelines that is confirmed by a sponsor-designated central laboratory
Descrição

HER2-positive carcinoma of breast

Tipo de dados

boolean

Alias
UMLS CUI [1]
C1960398
patients must have progressed on, or be intolerant to pertuzumab in the labc/mbc setting
Descrição

Disease Progression | Intolerance to Pertuzumab

Tipo de dados

boolean

Alias
UMLS CUI [1]
C0242656
UMLS CUI [2,1]
C1744706
UMLS CUI [2,2]
C1328025
patients must have progressed on, or be intolerant to ado-trastuzumab emtansine in the labc/mbc setting
Descrição

Disease Progression | Intolerance to Ado-trastuzumab emtansine

Tipo de dados

boolean

Alias
UMLS CUI [1]
C0242656
UMLS CUI [2,1]
C1744706
UMLS CUI [2,2]
C2935436
patients must have been previously treated with trastuzumab in any setting (which may have been previously administered with or without pertuzumab)
Descrição

Trastuzumab Previous | Pertuzumab Previous

Tipo de dados

boolean

Alias
UMLS CUI [1,1]
C0728747
UMLS CUI [1,2]
C0205156
UMLS CUI [2,1]
C1328025
UMLS CUI [2,2]
C0205156
ecog performance status of 0 or 1
Descrição

ECOG performance status

Tipo de dados

boolean

Alias
UMLS CUI [1]
C1520224
Exclusion Criteria
Descrição

Exclusion Criteria

Alias
UMLS CUI
C0680251
patients who have previously been treated with doxorubicin, liposomal doxorubicin, epirubicin, mitoxantrone, or any other anthracycline derivative
Descrição

Doxorubicin | doxorubicin liposome | Epirubicin | Mitoxantrone | Anthracycline Derivative

Tipo de dados

boolean

Alias
UMLS CUI [1]
C0013089
UMLS CUI [2]
C0717726
UMLS CUI [3]
C0014582
UMLS CUI [4]
C0026259
UMLS CUI [5,1]
C0282564
UMLS CUI [5,2]
C1527240
subjects with central nervous system (cns) metastases, unless they have been treated and are stable without symptoms for 4 weeks after completion of treatment and must be off steroids for at least 4 weeks prior to enrollment
Descrição

CNS metastases | Exception Treatment completed | Exception Stable status Without Symptoms | Exception Steroids Absent

Tipo de dados

boolean

Alias
UMLS CUI [1]
C0686377
UMLS CUI [2,1]
C1705847
UMLS CUI [2,2]
C0580352
UMLS CUI [3,1]
C1705847
UMLS CUI [3,2]
C0205360
UMLS CUI [3,3]
C0332288
UMLS CUI [3,4]
C1457887
UMLS CUI [4,1]
C1705847
UMLS CUI [4,2]
C0038317
UMLS CUI [4,3]
C0332197
patients with any class of new york heart association (nyha) chf or heart failure with preserved ejection fraction (hfpef)
Descrição

Congestive heart failure New York Heart Association Classification | Heart failure with preserved ejection fraction [HFpEF]

Tipo de dados

boolean

Alias
UMLS CUI [1,1]
C0018802
UMLS CUI [1,2]
C1275491
UMLS CUI [2]
C4509226
patients with a history of known coronary artery disease or a myocardial infarction within the last 12 months
Descrição

Coronary Artery Disease | Myocardial Infarction

Tipo de dados

boolean

Alias
UMLS CUI [1]
C1956346
UMLS CUI [2]
C0027051
patients with a known history of serious cardiac arrhythmias requiring treatment (exception: controlled atrial fibrillation, paroxysmal supraventricular tachycardia)
Descrição

Cardiac Arrhythmia Serious Treatment required for | Exception Controlled atrial fibrillation | Exception Paroxysmal supraventricular tachycardia

Tipo de dados

boolean

Alias
UMLS CUI [1,1]
C0003811
UMLS CUI [1,2]
C0205404
UMLS CUI [1,3]
C0332121
UMLS CUI [2,1]
C1705847
UMLS CUI [2,2]
C0577699
UMLS CUI [3,1]
C1705847
UMLS CUI [3,2]
C0030590
patients who previously discontinued trastuzumab due to unacceptable cardiac toxicity
Descrição

Trastuzumab Discontinued Due to Cardiotoxicity

Tipo de dados

boolean

Alias
UMLS CUI [1,1]
C0728747
UMLS CUI [1,2]
C1444662
UMLS CUI [1,3]
C0678226
UMLS CUI [1,4]
C0876994
patients with a history of lvef decline to below 50% during or after prior trastuzumab/lapatinib or other her2 directed therapy.
Descrição

Left ventricular ejection fraction | trastuzumab | lapatinib | HER2 Targeted Therapy

Tipo de dados

boolean

Alias
UMLS CUI [1]
C0428772
UMLS CUI [2]
C0728747
UMLS CUI [3]
C1506770
UMLS CUI [4,1]
C0069515
UMLS CUI [4,2]
C2985566
Voltar ao início da página

Similar models

Eligibility Breast Cancer NCT02213744

1 Formulários
Name
Tipo
Description | Question | Decode (Coded Value)
Tipo de dados
Alias
Item Group
C1512693 (UMLS CUI)
Invasive carcinoma of breast
Item
patients must have histologically or cytologically confirmed invasive cancer of the breast
boolean
C0853879 (UMLS CUI [1])
Advanced disease Locally | Neoplasm Metastasis | Excision Curative intent Unsuccessful
Item
patients must have documented locally advanced/metastatic disease, defined by the investigator, which is not amenable to resection with curative intent.
boolean
C0679246 (UMLS CUI [1,1])
C1517927 (UMLS CUI [1,2])
C0027627 (UMLS CUI [2])
C0728940 (UMLS CUI [3,1])
C1276305 (UMLS CUI [3,2])
C1272705 (UMLS CUI [3,3])
HER2-positive carcinoma of breast
Item
patients must have her2-positive breast cancer as defined by asco/cap 2013 guidelines that is confirmed by a sponsor-designated central laboratory
boolean
C1960398 (UMLS CUI [1])
Disease Progression | Intolerance to Pertuzumab
Item
patients must have progressed on, or be intolerant to pertuzumab in the labc/mbc setting
boolean
C0242656 (UMLS CUI [1])
C1744706 (UMLS CUI [2,1])
C1328025 (UMLS CUI [2,2])
Disease Progression | Intolerance to Ado-trastuzumab emtansine
Item
patients must have progressed on, or be intolerant to ado-trastuzumab emtansine in the labc/mbc setting
boolean
C0242656 (UMLS CUI [1])
C1744706 (UMLS CUI [2,1])
C2935436 (UMLS CUI [2,2])
Trastuzumab Previous | Pertuzumab Previous
Item
patients must have been previously treated with trastuzumab in any setting (which may have been previously administered with or without pertuzumab)
boolean
C0728747 (UMLS CUI [1,1])
C0205156 (UMLS CUI [1,2])
C1328025 (UMLS CUI [2,1])
C0205156 (UMLS CUI [2,2])
ECOG performance status
Item
ecog performance status of 0 or 1
boolean
C1520224 (UMLS CUI [1])
Item Group
C0680251 (UMLS CUI)
Doxorubicin | doxorubicin liposome | Epirubicin | Mitoxantrone | Anthracycline Derivative
Item
patients who have previously been treated with doxorubicin, liposomal doxorubicin, epirubicin, mitoxantrone, or any other anthracycline derivative
boolean
C0013089 (UMLS CUI [1])
C0717726 (UMLS CUI [2])
C0014582 (UMLS CUI [3])
C0026259 (UMLS CUI [4])
C0282564 (UMLS CUI [5,1])
C1527240 (UMLS CUI [5,2])
CNS metastases | Exception Treatment completed | Exception Stable status Without Symptoms | Exception Steroids Absent
Item
subjects with central nervous system (cns) metastases, unless they have been treated and are stable without symptoms for 4 weeks after completion of treatment and must be off steroids for at least 4 weeks prior to enrollment
boolean
C0686377 (UMLS CUI [1])
C1705847 (UMLS CUI [2,1])
C0580352 (UMLS CUI [2,2])
C1705847 (UMLS CUI [3,1])
C0205360 (UMLS CUI [3,2])
C0332288 (UMLS CUI [3,3])
C1457887 (UMLS CUI [3,4])
C1705847 (UMLS CUI [4,1])
C0038317 (UMLS CUI [4,2])
C0332197 (UMLS CUI [4,3])
Congestive heart failure New York Heart Association Classification | Heart failure with preserved ejection fraction [HFpEF]
Item
patients with any class of new york heart association (nyha) chf or heart failure with preserved ejection fraction (hfpef)
boolean
C0018802 (UMLS CUI [1,1])
C1275491 (UMLS CUI [1,2])
C4509226 (UMLS CUI [2])
Coronary Artery Disease | Myocardial Infarction
Item
patients with a history of known coronary artery disease or a myocardial infarction within the last 12 months
boolean
C1956346 (UMLS CUI [1])
C0027051 (UMLS CUI [2])
Cardiac Arrhythmia Serious Treatment required for | Exception Controlled atrial fibrillation | Exception Paroxysmal supraventricular tachycardia
Item
patients with a known history of serious cardiac arrhythmias requiring treatment (exception: controlled atrial fibrillation, paroxysmal supraventricular tachycardia)
boolean
C0003811 (UMLS CUI [1,1])
C0205404 (UMLS CUI [1,2])
C0332121 (UMLS CUI [1,3])
C1705847 (UMLS CUI [2,1])
C0577699 (UMLS CUI [2,2])
C1705847 (UMLS CUI [3,1])
C0030590 (UMLS CUI [3,2])
Trastuzumab Discontinued Due to Cardiotoxicity
Item
patients who previously discontinued trastuzumab due to unacceptable cardiac toxicity
boolean
C0728747 (UMLS CUI [1,1])
C1444662 (UMLS CUI [1,2])
C0678226 (UMLS CUI [1,3])
C0876994 (UMLS CUI [1,4])
Left ventricular ejection fraction | trastuzumab | lapatinib | HER2 Targeted Therapy
Item
patients with a history of lvef decline to below 50% during or after prior trastuzumab/lapatinib or other her2 directed therapy.
boolean
C0428772 (UMLS CUI [1])
C0728747 (UMLS CUI [2])
C1506770 (UMLS CUI [3])
C0069515 (UMLS CUI [4,1])
C2985566 (UMLS CUI [4,2])
Voltar ao início da página 

Contacto

Use este formulário para feedback, perguntas e sugestões de aperfeiçoamento.

Campos marcados com * são obrigatórios.

Ajuda

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial